SEC Form 4 · accession 0000899243-19-006734
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David McMullin
Officer — Chief Commercial Officer
Period of report
Mar 5, 2019
Accepted (ET)
Mar 7, 2019 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $8.05 | Mar 5, 2019 | A | 45,212 | A | — | Mar 4, 2029 | Common Stock | 45,212 | 45,212 | D |
Explanation of responses
- F1The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019.